Financial Statements

December 31, 2014 and 2013





Independent Auditors' Report

The Board of Trustees William T. Grant Foundation, Inc.

We have audited the accompanying financial statements of the William T. Grant Foundation, Inc. (the "Foundation"), which comprise the statements of financial position as of December 31, 2014 and 2013, and the related statements of activities and cash flows for the years then ended, and the related notes to the financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

The Board of Trustees William T. Grant Foundation, Inc. Page 2

Opinion

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the William T. Grant Foundation, Inc. as of December 31, 2014 and 2013 and the changes in its net assets and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America

Report on Supplementary Information

Our audits were conducted for the purpose of forming an opinion on the financial statements as a whole. The supplementary information included on pages 14, 15 and 16 is presented for purposes of additional analysis and is not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information, has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the financial statement themselves and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated in all material respects in relation to the financial statements as a whole.

O'Connor Davies, UP

October 12, 2015

Statements of Financial Position

	Dece	mber 31
	2014	2013
ASSETS Cash and cash equivalents Accrued investment income Due from investment managers Prepaid Federal excise tax Investments Prepaid expenses and other assets	\$ 4,019,484 63,687 - 78,000 328,375,552 48,567 \$ 332,585,290	\$ 9,405,303 70,549 1,725,302 - 313,118,008 48,695 \$ 324,367,857
LIABILITIES AND NET ASSETS Liabilities Accounts payable and accrued expenses Grants payable Federal excise tax payable Postretirement benefit obligation Deferred Federal excise tax Deferred rent Total Liabilities	\$ 330,194 10,232,798 - 2,465,788 1,655,000 <u>459,764</u> 15,143,544	\$ 352,462 10,434,971 128,000 2,956,931 1,670,000 <u>532,624</u> 16,074,988
Net assets	317,441,746	308,292,869
	<u>\$ 332,585,290</u>	<u>\$ 324,367,857</u>

See notes to financial statements

Statements of Activities

	Year Ended December 31		
	2014	2013	
REVENUE			
Investment Income			
Interest and dividends	\$ 6,217,241	\$ 5,927,662	
Less:			
Federal and state tax expense	295,216	590,046	
Investment expenses	1,086,105	1,018,445	
Net investment income	4,835,920	4,319,171	
Rental income	161,283	157,348	
Total Revenue	4,997,203	4,476,519	
	,	,	
EXPENSES			
Program Services			
Grants authorized, net of refunded and			
rescinded amount of \$109,045			
and \$59,825	10,963,903	10,680,794	
Program support, planning, and development	3,993,865	3,948,450	
Total Program Services	14,957,768	14,629,244	
Supporting Services - operations and governance	1,237,269	1,243,387	
Total Expenses	16,195,037	15,872,631	
Net realized and unrealized gains on investments,			
net of (benefit) provision for deferred Federal			
excise tax of (\$15,000) and \$438,000	19,746,071	42,202,011	
Change in Net Assets Before Postretirement Benefit			
Obligation Adjustment	8,548,237	30,805,899	
Postretirement benefit obligation adjustment	600,640	(169,765)	
Change in Net Assets	9,148,877	30,636,134	
NET ASSETS	200 202 060	277 656 725	
Beginning of year	308,292,869	277,656,735	
End of year	\$317,441,746	\$308,292,869	
	<u>,,</u>	<u>+++++++++++++++++++++++++++++++++++++</u>	

Statements of Cash Flows

		Ended
	Decen	nber 31
	2014	2013
CASH FLOWS FROM OPERATING ACTIVITIES		
Change in net assets	\$ 9,148,877	\$ 30,636,134
Adjustments to reconcile change in net assets		
to net cash from operating activities		
Net realized gains on sale of investments	(17,093,782)	(20,840,200)
Unrealized loss (gain) on investments	(2,637,289)	(21,799,811)
Deferred Federal excise tax	(15,000)	438,000
Postretirement benefit obligation adjustment	(600,640)	169,765
Amortization of deferred rent	(72,860)	2,125
Net changes in operating assets and liabilities		
Accrued investment income	6,862	3,984
Due from investment managers	1,725,302	(1,703,552)
Prepaid Federal excise tax	(78,000)	91,000
Prepaid expenses and other assets	128	(26,243)
Accounts payable and accrued expenses	(22,268)	58,032
Grants payable	(202,173)	925,748
Federal excise tax payable	(128,000)	128,000
Postretirement benefit obligation	109,497	22,363
Net Cash from Operating Activities	(9,859,346)	(11,894,655)
CASH FLOWS FROM INVESTING ACTIVITIES		
Proceeds from sale of investments	55,265,259	67,589,787
Purchase of investments	(50,791,732)	(59,571,135)
Net Cash from Investing Activities	4,473,527	8,018,652
Net Change in Cash and Cash Equivalents	(5,385,819)	(3,876,003)
CASH AND CASH EQUIVALENTS		
Beginning of year	9,405,303	13,281,306
End of year	<u>\$ 4,019,484</u>	<u>\$ 9,405,303</u>
SUPPLEMENTAL CASH FLOW INFORMATION		
Cash paid for Federal and state taxes on investment income	\$ 369,230	\$ 369,230

Notes to Financial Statements December 31, 2014 and 2013

1. Organization

William T. Grant Foundation, Inc. (the Foundation) was established by William T. Grant in 1936. The goal of the Foundation is to support research that improves the lives of young people. The primary source of revenue for the Foundation is its investment activities.

2. Summary of Significant Accounting Policies

Basis of Presentation and Use of Estimates

The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"), which requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Accordingly actual results could differ for those estimates.

Cash and Cash Equivalents

Cash and cash equivalents represent short-term investments with maturities of three months or less at time of purchase except for those short-term investments managed by the Foundation's investment managers as part of their long-term investment strategies.

Fair Value Measurements

The Foundation follows U.S. GAAP guidance on Fair Value Measurements which defines fair value and establishes a fair value hierarchy organized into three levels based upon the input assumptions used in pricing assets. Level 1 inputs have the highest reliability and are related to assets with unadjusted quoted prices in active markets. Level 2 inputs relate to assets with other than quoted prices in active markets which may include quoted prices for similar assets or liabilities or other inputs which can be corroborated by observable market data. Level 3 inputs are unobservable inputs and are used to the extent that observable inputs do not exist.

Investments Valuation

Other than cash and cash equivalents, investments are stated at fair value. The fair value of alternative investments has been estimated using the Net Asset Value ("NAV") as reported by the management of the respective alternative investment fund. U.S. GAAP guidance provides for the use of NAV as a "Practical Expedient" for estimating fair value of alternative investments. NAV reported by each alternative investment fund is used as a practical expedient to estimate the fair value of the Foundation's interest therein and their classification within Level 2 or 3 is based on the Foundation's ability to redeem its interest in the near term.

Investment Income Recognition

Purchases and sales of securities are recorded on a trade-date basis. Interest income is recorded on the accrual basis and dividends are recorded on the ex-dividend date. Realized gains and losses on the sale of investments are computed on the specific identification basis. Realized and unrealized gains and losses are included in the determination of the change in net assets.

Notes to Financial Statements December 31, 2014 and 2013

2. Summary of Significant Accounting Policies (*continued*)

Fair Value of Financial Instruments

The estimated fair value of the Foundation's financial instruments, including cash, approximate carrying amounts due to the short-term maturities of these instruments.

Property and Equipment

The cost of office furniture, leasehold improvements, fixtures, and equipment purchased during the course of normal business activities is charged to operations when purchased, as such purchases are not significant.

Grants

Grants are recorded when authorized by either the Board of Trustees or by officers of the Foundation within limits specified by the Board of Trustees.

Postretirement Benefit Plan

The Foundation follows U.S. GAAP guidance on Defined Benefit Plans which requires the Foundation to recognize the funded status of the Foundation's postretirement medical and health benefits as an asset or liability in its statement of financial position with a corresponding adjustment to change in net assets in the statement of activities. The adjustment to change in net assets represents the balance of unrecognized actuarial gains that will be recognized within net periodic cost in the future.

Net Asset Presentation

Net assets and revenues, expenses, gains and losses are classified based on the existence or absence of donor imposed restrictions. The Foundation's net assets are neither permanently nor temporarily restricted by donor imposed restrictions and are classified as unrestricted.

Accounting for Uncertainty in Income Taxes

The Foundation recognizes the effect of tax positions only if they are more likely than not to be sustained. Management has determined that the Foundation had no uncertain tax positions that would require financial statement disclosure and/or recognition. The Foundation is no longer subject to examinations by the applicable jurisdictions for periods prior to December 31, 2011.

Subsequent Events Evaluation by Management

Management has evaluated subsequent events for disclosure and/or recognition in the financial statements through the date that the financial statements were available to be issued, which date is October 12, 2015.

Notes to Financial Statements December 31, 2014 and 2013

3. Investments

Hedge funds(a)

The following are major categories of investments measured at fair value on a recurring basis at December 31, grouped by their fair value hierarchy:

				20	14		
Description		(Level 1)	(Le	evel 2)		vel 3)	 Total
Cash held for investments Equity Securities	\$	2,626,530	\$	-	\$	-	\$ 2,626,530
US regulated investment company-non US		14,098,707		-		-	14,098,707
Diversified emerging markets		12,807,254		-		-	12,807,254
Global equity portfolio		17,013,911		-		-	17,013,911
Financial services		14,171,898		-		-	14,171,898
Technology		13,981,184		-		-	13,981,184
Services		8,758,942		-		-	8,758,942
Consumer staples		6,002,216		-		-	6,002,216
Other Fixed Income		36,306,098		-		-	36,306,098
Mutual funds		18,343,315		-		-	18,343,315
Short term bond		12,019,940		-		-	12,019,940
Emergings markets bond Alternative Investments		-	16	561,564		-	16,561,564
Hedge funds(a)		-	56	273,270	15,	291,604	71,564,874
Private equity(a)		-		-		119,119	84,119,119
Total Investments at Fair Value	\$	156,129,995	\$72	834,834	\$99,	410,723	\$ 328,375,552
				20)13		
Description	_	(Level 1)	(Le	evel 2)	(Le	evel 3)	 Total
Cash held for investments Equity Securities	\$	2,529,264	\$	-	\$	-	\$ 2,529,264
US regulated investment company-non US		14,166,119		-		-	14,166,119
US regulated investment company		13,465,326		-		-	13,465,326
Diversified emerging markets		16,169,191		-		-	16,169,191
Global equity portfolio		12,683,371		-		-	12,683,371
Financial services		13,274,189		-		-	13,274,189
Consumer staples		8,460,601		-		-	8,460,601
Technology		6,868,752		-		-	6,868,752
Other		34,832,866		-		-	34,832,866
Fixed Income							,,,,,,,,,,,
Mutual funds		17,946,447		-		-	17,946,447
US regulated investment company		5,152,746		-		-	5,152,746
Emerging markets bond Alternative investments		-	15	,627,572		-	15,627,572

Private equity(a)		-	81,413,041	81,413,041
Total Investments at Fair Value	<u>\$ 145,548,872</u>	<u>\$ 71,956,300</u>	<u>\$ 95,612,836</u>	<u>\$ 313,118,008</u>

-

56,328,728

14,199,795

70,528,523

(a) Based on its analysis of the nature and risk of these investments, the Foundation has determined that presenting them as a single class is appropriate.

Notes to Financial Statements December 31, 2014 and 2013

3. Investments (continued)

Investments account for all assets measured at fair value at December 31, 2014 and 2013.

The following is a reconciliation of the Level 3 investments valued using NAV as practical expedient during the years ended December 31:

		2014	
	Hedge Funds	Private Equity	Total
Beginning balance	\$ 14,199,795	\$ 81,413,041	\$ 95,612,836
Total realized gains included in changes in net assets	-	10,456,269	10,456,269
Unrealized gains related to instruments still held at reporting date included in earnings	1,091,809	3,588,720	4,680,529
Purchases, issuances and (settlements), net		(11,338,911)	(11,338,911)
Ending balance	\$ 15,291,604	<u>\$ 84,119,119</u>	<u>\$ 99,410,723</u>
		2013	
	Hedge Funds	Private Equity	Total
Beginning balance	\$ 11,858,740	\$ 79,287,800	\$ 91,146,540
Total realized gain included in changes in net assets	-	13,789,997	13,789,997
Unrealized gains (losses) related to instruments still held at reporting date included in earnings	2,341,055	(501,993)	1,839,062
	2,341,055	(501,993) (11,162,763)	1,839,062 (11,162,763)

Information regarding Level 2 and 3 investments valued using NAV as practical expedient at December 31, 2014 is as follows:

	Fair Value	Unfunded Commitments	Redemption Frequency (If Currently Eligible)	Redemption Notice Period
Hedge Funds (see "a" below) Private Equity (see "b" below)	\$ 71,564,874 <u>84,119,119</u> \$ 155,683,993	\$	Monthly - Annually Locked	20-90 days N/A

Notes to Financial Statements December 31, 2014 and 2013

3. Investments (continued)

a. This category includes investments in "hedge funds" that invest predominantly in limited partnerships, similar pooled investment vehicles and direct investments in securities and loans. These funds were primarily formed with the purpose of achieving long-term growth of capital with reduced volatility by allocating its capital among various money managers. The fair value of investments in this category has been estimated using the net asset value per share of the investments. Investments in this category may be redeemed monthly to quarterly, in whole or in part, subject to written notice before the prior quarter's close.

b. This category includes several private equity funds that invest primarily in private equity investment partnerships. The fair values of the investments in this category have been estimated using the net asset value of the Foundation's ownership interest in partners' capital. These investments can never be redeemed with the funds. Instead, the nature of the investments in this category is that distributions are received through liquidation of the underlying assets of the fund. Management has estimated that the underlying assets of these funds will be liquidated over 1 to 8 years.

Alternative investments consist of non-traditional, not readily marketable investments, some of which may be structured as offshore limited partnerships, venture capital funds, hedge funds, private equity funds and common trust funds. The underlying investments of such funds, whether invested in stock or other securities, are generally not currently traded in a public market and typically are subject to restrictions on resale. Values determined by investment managers and general partners of underlying securities that are thinly traded or not traded in an active market may be based on historical cost, appraisals, a review of the investees' financial results, financial condition and prospects, together with comparisons to similar companies for which quoted market prices are available or other estimates that require varying degrees of judgment.

Because of the inherent uncertainty of valuations, the estimated fair values may differ significantly from the values that would have been used had a ready market for such investments existed or had such investments been liquidated, and those differences could be material.

4. Grants Payable

The following summarizes changes in grants payable as of December 31:

	2014	2013
Balance at beginning of year	\$ 10,434,971	\$ 9,509,223
Addition: Grants authorized	11,072,948	10,740,569
Deductions: Payments made	(11,275,121)	(9,814,771)
Rescinded amounts		(50)
	\$ 10,232,798	\$ 10,434,971

Notes to Financial Statements December 31, 2014 and 2013

4. Grants Payable (continued)

Grants payable are scheduled to be disbursed as follows:

2015	\$ 5,483,426
2016	3,300,823
2017	1,065,305
2018	 383,244
	\$ 10,232,798

5. Lease Commitment

The Foundation has a lease agreement for office space which expires on September 30, 2018. The lease contains escalation clauses that provide for increased payments resulting from increases in real estate taxes and certain other building expenses in excess of the base period amounts. Future minimum rental payments under this lease are as follows:

	\$ 4,434,829
2018	 908,612
2017	1,195,855
2016	1,175,288
2015	\$ 1,155,074

In August 2012 the Foundation entered into an agreement to sublease a portion of its space expiring September 2018. This agreement requires monthly payments to the Foundation of approximately \$13,000 for the first twelve months increasing to approximately \$15,000 for the last twelve months.

6. Retirement Benefits

Retirement benefits under a defined contribution plan are provided through the Teacher's Insurance and Annuity Association to all permanent employees who have completed six months of continuous service. Contributions are expensed when made. Plan expenses in 2014 and 2013 were \$272,981 and \$262,798.

7. Postretirement Healthcare Benefits

In addition to the above retirement plan, the Foundation sponsors an unfunded plan to provide certain health care benefits for retirees of the Foundation. The Foundation funds its postretirement benefits costs on a pay as you go basis.

Notes to Financial Statements December 31, 2014 and 2013

7. Postretirement Healthcare Benefits (continued)

Information as of and for the years ended December 31 for the plan is as follows:

	2014	2013
Benefit Obligation (Funded Status)		
at End of Year	\$ 2,465,788	\$ 2,956,931
Net postretirement benefit costs	235,038	148,144
Unrecognized actuarial (gain) loss	(600,640)	169,765
Benefits paid	125,541	125,781
Discount rate used	3.74%	4.65%
Components of Net Periodic Expense		
for the Year	2014	2013
Service cost	\$ 103,378	\$ 48,125
Interest cost	131,660	100,019
	<u>\$ 235,038</u>	<u>\$ 148,144</u>
	Increase	(Decrease)
	2014	2013
Effect of a one-percent point increase in HCCTR* on		
Year end benefit obligation Total of service and interest	\$ 321,466	\$ 377,063
cost component	140,138	268,808
Effect of a one-percent point decrease in HCCTR* on		
Year end benefit obligation Total of service and interest	(267,257)	(314,985)
cost component	(103,834)	(200,266)

* Health Care Cost Trend Rate

Measurements used to determine the postretirement benefit obligation for the years ended 2014 and 2013 were computed as of December 31.

For measurement purposes, an 15% annual rate of increase in per capita cost of covered health benefits was assumed for 2014, decreasing to 5.5% in 2020 and thereafter.

Notes to Financial Statements December 31, 2014 and 2013

7. Postretirement Healthcare Benefits (continued)

Net benefits expected to be paid in each of the next five years and the following five years in the aggregate are as follows:

2015	\$ 127,	311
2016	134,	068
2017	135,	908
2018	136,	993
2019	132,	993
2020-2024	700,	392
	<u>\$ 1,367,</u>	665

8. Federal Excise Taxes

The Foundation is nonprofit organization exempt from Federal income taxes under the provisions of Section 501(c)(3) of the Internal Revenue Code (the Code), and is a private foundation as defined in Section 509(a) of the Code. The Foundation is subject to a Federal excise tax of 2% on its net investment income, as defined, for tax purposes. However, the excise tax can be reduced to 1% if certain conditions are met. Deferred taxes arise from differences between the cost and fair value of investments.

* * * * *

Supplementary Information

December 31, 2014

Portfolio Asset Allocation Schedule December 31, 2014

	Fair Value	% of Portfolio	Target Allocation	Target Range
EQUITY				
U.S.:				
Silvercrest Asset Management Group	\$ 23,080,107			
Eagle Capital Equity	29,885,083			
Wasatch (small cap growth)	23,040,384			
Subtotal U.S.	76,005,574	23.1%		
GLOBAL				
First Eagle	14,098,707			
Global Thematic Equity	18,343,315			
Harding & Loevner	17,013,911			
Subtotal Global	49,455,933	15.1%		
EMERGING MARKETS				
Dimensional Fund Advisors	12,807,254			
TVC Conduit	5,841,294			
Subtotal Emerging Markets	18,648,548	5.7%		
Subtotal Long Equity	144,110,055	43.9%		
HEDGED				
New Generation Turnaround Fund	21,861,706			
New Mountain Vantage	15,291,604			
Steelhead Partners	19,323,136			
Blenheim Commodities Fund	8,388,133			
High Vista II	6,700,295	04.00/		
Subtotal Hedged	71,564,874	21.8%	50.00/	
Total Equity (including limited partnerships)	215,674,929	65.7%	58.0%	40.0-70.0%
ALTERNATIVE INVESTMENTS				
Altira Technology Fund II	71,556			
Altira Technology Fund III	310,573			
Altira Technology Fund IV American Securities Partners III	118,600 1,053,008			
American Securities Partners IV	1,931,089			
American Securities Partners V	3,767,694			
BioPharma Sec. Debt	3,532,209			
Brightwood Capital	4,538,814			
Capital Dynamics Champion Ventures IV	1,611,710			
Cross Creek Capital	3,433,586			
Crystal Ridge Partners	2,847,609			
CSL Energy Easterly Prt US Govt Inc & Growth I	2,986,119 6,420,440			
Easterly Prt US Govt Inc & Growth II	3,832,209			
North Atlantic Venture	600,000			
Paul Capital Royalty Fund	778,305			
Royalty Pharma	13,165,459			
TIFF Partners II	96,708			
TIFF Partners V Domestic	2,228,163			
TIFF Partners V International	1,727,216			
TIFF Private Equity Partners 2006	2,302,871			
TIFF Private Equity Partners 2007	7,346,816			
TIFF Private Equity Partners 2008	11,475,889			
TIFF Secondary Partners II	3,110,642			
TIFF Special Opportunities	2,062,890			
Venture Investment Total Alternatives Investments	<u>2,768,944</u> 84,119,119	25.6%	12.0%	10.0-20.0%
	,,	20.070	12.070	10.0 20.070
FIXED INCOME GMO Emerging Country Debt Fund	16,561,564			
JPM Short Duration Bond	2,004,110			
JPM Management Income Fund	10,015,830			
Total Fixed Income	28,581,504	<u>8.7%</u>	30.0%	20.0-50.0%
Total Portfolio	\$ 328,375,552	<u>100.0</u> %	<u>100.0</u> %	

See independent auditors' report

Fair Value Measurements of Portfolio Assets December 31, 2014

Eagle Capital Equity29.8Wasatch (small cap growth)23.0Subtotal U.S.76.0GLOBALFirst EagleFirst Eagle14.0Global Thematic Equity18.3Harding & Loevner17.0Subtotal Global49.4EMERGING MARKETS18.6Dimensional Fund Advisors12.8TVC Conduit5.8Subtotal Long Equity144.1HEDGED15.2New Generation Turnaround Fund21.8New Generation Turnaround Fund8.3High Vista II6.7Subtotal Hedged71.5Total Equity (including limited partnerships)215.6ALTERNATIVE INVESTMENTS1.0Attira Technology Fund II3Attira Technology Fund II1.0American Securities Partners III1.0American Securities Partners IV1.9American Securities Partners IV3.7Biopharma Sec. Debt3.5Brightwood Capital4.5Capital Dynamics Champion Ventures IV1.6Cross Creek Capital3.4Crystal Ridge Partners2.8CSL Energy2.9Easterly Prt US Govt Inc & Growth I6.4Easterly Prt US Govt Inc & Growth I6.4Easterly Prt US Govt Inc & Growth I6.4Paul Capital Royalty Fund7Royalty Pharma13.1		083 - 384 - 574 - 707 - 315 - 911 - 933 - 254 - 294 - 548 - 055 - - 21,861,706 - - 19,323,136 - 8,388,133 - 6,700,295	Level 3
EQUITY U.S.: Silvercrest Asset Management Group Eagle Capital Equity Wasatch (small cap growth) Subtotal U.S. GLOBAL First Eagle First Eagle Obal Thematic Equity Harding & Loevner Subtotal Global EMERGING MARKETS Dimensional Fund Advisors TVC Conduit Subtotal Long Equity HEDGED New Generation Turnaround Fund New Generation Turnaround Fund New Mountain Vantage Subtotal Hedged 71.5 Total Equity (including limited partnerships) 215.6 ALTERNATIVE INVESTMENTS Altira Technology Fund II American Securities Partners IV American Securities Partners IV American Securities Partners IV American Securities Partners II Gross Creek Capital Crystal Ridge Partners SiloPharma Sec. Debt Brightwood Capital Capital Dynamics Champion Ventures IV Crystal Ridge Partners Paul Capital Royalty Fund	080,107 \$ 23,080, 085,083 29,885, 040,384 23,040, 005,574 76,005, 098,707 14,098, 343,315 18,343, 113,911 17,013, 14,55,933 49,455, 307,254 12,807, 341,294 5,841, 548,548 18,648,4 110,055 144,110, 361,706 291,604 323,136 388,133	107 \$ - 083 - 384 - 574 - 577 - 315 - 911 - 933 - 254 - 294 - 548 - 055 - - 21,861,706 - - - 19,323,136 - 8,388,133 - 6,700,295	\$
U.S.: Silvercrest Asset Management Group Eagle Capital Equity Wasatch (small cap growth) Subtotal U.S. GLOBAL First Eagle first Eagle first Eagle Global Thematic Equity Harding & Loevner Subtotal Global HerrGING MARKETS Dimensional Fund Advisors TVC Conduit Subtotal Emerging Markets Subtotal Emerging Markets Subtotal Long Equity HEDGED New Generation Turnaround Fund New Generation Turnaround Fund New Generation Turnaround Fund New Generation Turnaround Fund Stelehead Partners Blenheim Commodities Fund High Vista II Subtotal Equity (including limited partnerships) Z15.6 Total Equity (including limited partnerships) Z15.6 ALTERNATIVE INVESTMENTS Altira Technology Fund II American Securities Partners III American Securities Partners IV American Securities Partners IV Sightwood Capital Capital Dynamics Champion Ventures IV Capital Dynamics Champion Ventures IV Capital Ridge Partners 2.8 CSL Energy Easterly Prt US Govt Inc & Growth I Basterly Prt US Govt Inc & Growth I Basterly Prt US Govt Inc & Growth I Basterly Pharma Basterly	385,083 29,885,1 040,384 23,040,3 005,574 76,005,5 098,707 14,098,7 343,315 18,343,7 13,911 17,013,1 14,55,933 49,455,5 307,254 12,807,7 341,294 5,841,7 548,548 18,648,4 110,055 144,110,1 361,706 291,604 323,136 388,133	083 - 384 - 574 - 707 - 315 - 911 - 933 - 254 - 294 - 548 - 055 - - 21,861,706 - - 19,323,136 - 8,388,133 - 6,700,295	
Silvercrest Asset Management Group\$ 23,0Eagle Capital Equity29,8Wasatch (small cap growth)23,0Subtotal U.S.76,0GLOBAL76,0First Eagle14,0Global Thematic Equity18,3Harding & Loevner17,0Subtotal Global49,4EMERGING MARKETS12,8Dimensional Fund Advisors12,8TVC Conduit5,8Subtotal Long Equity144,1HEDGED14,0New Generation Turnaround Fund21,8New Mountain Vantage15,2Steelhead Partners19,3Bienheim Commodities Fund8,3High Vista II6,7Subtotal Hedged71,5Total Equity (including limited partnerships)215,6Altira Technology Fund II3Altira Technology Fund II3,1Attira Technology Fund II1,0American Securities Partners III1,0American Securities Partners IV3,7BioPharma Sec. Debt3,5Brightwood Capital4,5Capital Dynamics Champion Ventures IV1,6Cross Creek Capital3,4Crystal Ridge Partners2,8North Atlantic Venture6Paul Capital Royalty Fund7Royalty Pharma13,1	385,083 29,885,1 040,384 23,040,3 005,574 76,005,5 098,707 14,098,7 343,315 18,343,7 13,911 17,013,1 14,55,933 49,455,5 307,254 12,807,7 341,294 5,841,7 548,548 18,648,4 110,055 144,110,1 361,706 291,604 323,136 388,133	083 - 384 - 574 - 707 - 315 - 911 - 933 - 254 - 294 - 548 - 055 - - 21,861,706 - - 19,323,136 - 8,388,133 - 6,700,295	
Eagle Capital Equity29.8Wasatch (small cap growth)23.0Subtotal U.S.76.0GLOBALFirst Eagle14.0Global Thematic Equity18.3Harding & Loevner17.0Subtotal Global49.4EMERGING MARKETSDimensional Fund Advisors12.8TVC Conduit5.8Subtotal Emerging Markets18.6Subtotal Long Equity144.1HEDGEDNew Generation Turnaround Fund21.8New Generation Turnaround Fund21.8New Generation Turnaround Fund8.3High Vista II6.7Subtotal Hedged71.5Total Equity (including limited partnerships)215.6ALTERNATIVE INVESTMENTS1.9Attira Technology Fund II3Attira Technology Fund II1.0American Securities Partners III1.0American Securities Partners IV1.9American Securities Partners IV3.7BioPharma Sec. Debt3.5Birghtwood Capital4.5Capital Dynamics Champion Ventures IV1.6Cross Creek Capital3.4Crystal Ridge Partners2.8SLE Energy2.9Easterly Prt US Govt Inc & Growth I6.4Easterly Prt US Govt Inc & Growth I6.4	385,083 29,885,1 040,384 23,040,3 005,574 76,005,5 098,707 14,098,7 343,315 18,343,7 13,911 17,013,1 14,55,933 49,455,5 307,254 12,807,7 341,294 5,841,7 548,548 18,648,4 110,055 144,110,1 361,706 291,604 323,136 388,133	083 - 384 - 574 - 707 - 315 - 911 - 933 - 254 - 294 - 548 - 055 - - 21,861,706 - - 19,323,136 - 8,388,133 - 6,700,295	
Wasatch (small cap growth) 23,0 Subtotal U.S. 76,0 GLOBAL 14,0 First Eagle 14,0 Global Thematic Equity 18,3 Harding & Loevner 17,0 Subtotal Global 49,4 EMERGING MARKETS 12,8 Dimensional Fund Advisors 12,8 TVC Conduit 5,8 Subtotal Emerging Markets 18,6 Subtotal Long Equity 144,1 HEDGED 144,1 New Generation Turnaround Fund 21,8 New Mountain Vantage 15,2 Steelhead Partners 19,3 Blenheim Commodities Fund 8,3 High Vista II 6,7 Subtotal Hedged 71,5 Total Equity (including limited partnerships) 215,6 ALTERNATIVE INVESTMENTS 1,0 Attira Technology Fund II 3 Attira Technology Fund II 1,0 American Securities Partners IV 1,9 American Securities Partners IV 3,7 BioPharma Sec. Debt 3,5 Brightwood Capital 4,5 <tr< td=""><td>040,384 23,040,3 005,574 76,005,3 098,707 14,098,7 043,315 18,343,3 013,911 17,013,3 14,55,933 49,455,3 307,254 12,807,3 341,294 5,841,3 548,548 18,648,3 110,055 144,110,1 361,706 291,604 323,136 388,133</td><td>384 - 574 - 574 - 707 - 315 - 933 - 933 - 254 - 294 - 548 - 055 - - 21,861,706 - - - 19,323,136 - 8,388,133 - 6,700,295</td><td>- - - - - - - - - - - - - - - - - - -</td></tr<>	040,384 23,040,3 005,574 76,005,3 098,707 14,098,7 043,315 18,343,3 013,911 17,013,3 14,55,933 49,455,3 307,254 12,807,3 341,294 5,841,3 548,548 18,648,3 110,055 144,110,1 361,706 291,604 323,136 388,133	384 - 574 - 574 - 707 - 315 - 933 - 933 - 254 - 294 - 548 - 055 - - 21,861,706 - - - 19,323,136 - 8,388,133 - 6,700,295	- - - - - - - - - - - - - - - - - - -
Subtotal U.S.76.0GLOBALFirst Eagle14.0Global Thematic Equity18.3Harding & Loevner17.0Subtotal Global49.4EMERGING MARKETS12.8Dimensional Fund Advisors12.8TVC Conduit5.8Subtotal Emerging Markets18.6Subtotal Long Equity144.1HEDGEDNew Generation Turnaround Fund21.8New Generation Turnaround Fund21.8New Mountain Vantage15.2Steelhead Partners19.3Blenheim Commodities Fund8.3High Vista II6.7Subtotal Hedged71.5Total Equity (including limited partnerships)215.6ALTERNATIVE INVESTMENTS3.7Altira Technology Fund II10American Securities Partners III1.0American Securities Partners IV1.9American Securities Partners V3.7BioPharma Sec. Debt3.5Brightwood Capital4.5Capital Dynamics Champion Ventures IV1.6Cross Creek Capital3.4Crystal Ridge Partners2.8CSL Energy2.9Easterly Prt US Govt Inc & Growth I6.4Easterly Prt US Govt Inc & Growth I6.4Easterly Prt US Govt Inc & Growth I6.4Easterly Pharma13.1	005,574 76,005,574 098,707 14,098,703 343,315 18,343,315 013,911 17,013,315 155,933 49,455,51 307,254 12,807,7 341,294 5,841,7 548,548 18,648,81 110,055 144,110,0 361,706 291,604 323,136 388,133	574 - 707 - 315 - 911 - 933 - 254 - 294 - 548 - 055 - - 21,861,706 - 19,323,136 - 8,388,133 - 6,700,295	
GLOBAL First Eagle 14.0 Global Thematic Equity 18.3 Harding & Loevner 17.0 Subtotal Global 49.4 EMERGING MARKETS 12.8 Dimensional Fund Advisors 12.8 TVC Conduit 5.8 Subtotal Emerging Markets 18.6 Subtotal Long Equity 144.1 HEDGED 144.1 New Generation Turnaround Fund 21.8 New Mountain Vantage 15.2 Steelhead Partners 19.3 Blenheim Commodities Fund 8.3 High Vista II 6.7 Subtotal Hedged 71.5 Total Equity (including limited partnerships) 215.6 ALTERNATIVE INVESTMENTS 14 Altira Technology Fund II 10 American Securities Partners IV 19 American Securities Partners IV 19.9 Brightwood Capital 4.5 Capital Dynamics Champion Ventures IV 1.6 Cross Creek Capital 3.4 Crystal Ridge Partners 2.8 Easterly Prt US Govt Inc & Growth I 6.4	098,707 14,098,703 343,315 18,343,703 013,911 17,013,703,703 1455,933 49,455,703 307,254 12,807,703 341,294 5,841,703 548,548 18,648,703 110,055 144,110,103 361,706 291,604 323,136 388,133	707 - 315 - 911 - 933 - 254 - 294 - 548 - 055 - - 21,861,706 - 19,323,136 - 8,388,133 - 6,700,295	
First Eagle14,0Global Thematic Equity18,3Harding & Loevner17,0Subtotal Global49,4EMERGING MARKETS12,8Dimensional Fund Advisors12,8TVC Conduit5.8Subtotal Emerging Markets18,6Subtotal Long Equity144,1HEDGED144,1New Generation Turnaround Fund21,8New Generation Turnaround Fund21,8New Generation Turnaround Fund8,3High Vista II6,7Subtotal Hedged71,5Total Equity (including limited partnerships)215,6ALTERNATIVE INVESTMENTS4Altira Technology Fund II1,0American Securities Partners IV1,9American Securities Partners IV3,5Bightwood Capital4,5Capital Dynamics Champion Ventures IV1,6Cross Creek Capital3,4Crystal Ridge Partners2,9Easterly Prt US Govt Inc & Growth I6,4Easterly Prt US Govt Inc & Growth I3,8North Atlantic Venture6Paul Capital Royalty Fund7Royalty Pharma13,1	343,315 18,343,315 013,911 17,013,315 155,933 49,455,133 307,254 12,807,315 341,294 5,841,315 348,548 18,648,315 110,055 144,110,015 3661,706 291,604 323,136 388,133	315 - 911 - 933 - 254 - 294 - 548 - 055 - - 21,861,706 - - - 19,323,136 - 8,388,133 - 6,700,295	- - - - - - - - - - - - - - - - - - -
Global Thematic Equity18,3Harding & Loevner17,0Subtotal Global49,4EMERGING MARKETS12,8Dimensional Fund Advisors12,8TVC Conduit5,8Subtotal Emerging Markets18,6Subtotal Long Equity144,1HEDGED144,1HEDGED144,1New Generation Turnaround Fund21,8New Mountain Vantage15,2Steelhead Partners19,3Blenheim Commodities Fund8,3High Vista II6,7Subtotal Hedged71,5Total Equity (including limited partnerships)215,6ALTERNATIVE INVESTMENTS1,0Attira Technology Fund II1Attira Technology Fund II1,0American Securities Partners IV1,9American Securities Partners IV3,7BioPharma Sec. Debt3,5Brightwood Capital4,5Capital Dynamics Champion Ventures IV1,6Cross Creek Capital3,4Crystal Ridge Partners2,8CSL Energy2,9Easterly Prt US Govt Inc & Growth I6,4Easterly Prt US Govt Inc & Growth I3,8North Atlanic Venture6Paul Capital Royalty Fund7Royalty Pharma13,1	343,315 18,343,315 013,911 17,013,315 155,933 49,455,133 307,254 12,807,315 341,294 5,841,315 348,548 18,648,315 110,055 144,110,015 3661,706 291,604 323,136 388,133	315 - 911 - 933 - 254 - 294 - 548 - 055 - - 21,861,706 - - - 19,323,136 - 8,388,133 - 6,700,295	- - - - - - - - - - - - - - - - - - -
Global Thematic Equity18,3Harding & Loevner17,0Subtotal Global49,4EMERGING MARKETS12,8Dimensional Fund Advisors12,8TVC Conduit5,8Subtotal Emerging Markets18,6Subtotal Long Equity144,1HEDGED144,1HEDGED144,1New Generation Turnaround Fund21,8New Mountain Vantage15,2Steelhead Partners19,3Blenheim Commodities Fund8,3High Vista II6,7Subtotal Hedged71,5Total Equity (including limited partnerships)215,6ALTERNATIVE INVESTMENTS1,0Attira Technology Fund II1Attira Technology Fund II1,0American Securities Partners IV1,9American Securities Partners IV3,7BioPharma Sec. Debt3,5Brightwood Capital4,5Capital Dynamics Champion Ventures IV1,6Cross Creek Capital3,4Crystal Ridge Partners2,8CSL Energy2,9Easterly Prt US Govt Inc & Growth I6,4Easterly Prt US Govt Inc & Growth I3,8North Atlanic Venture6Paul Capital Royalty Fund7Royalty Pharma13,1	343,315 18,343,315 013,911 17,013,315 155,933 49,455,133 307,254 12,807,315 341,294 5,841,315 348,548 18,648,315 110,055 144,110,015 3661,706 291,604 323,136 388,133	315 - 911 - 933 - 254 - 294 - 548 - 055 - - 21,861,706 - - - 19,323,136 - 8,388,133 - 6,700,295	- - - - - - - - - - - - - - - - - - -
Harding & Loevner17.0Subtotal Global49.4EMERGING MARKETS12.8Dimensional Fund Advisors12.8TVC Conduit5.8Subtotal Emerging Markets18.6Subtotal Long Equity144.1HEDGED144.1New Generation Turnaround Fund21.8New Mountain Vantage15.2Steelhead Partners19.3Blenheim Commodities Fund8.3High Vista II6.7Subtotal Hedged71.5Total Equity (including limited partnerships)215.6ALTERNATIVE INVESTMENTS1.9Altira Technology Fund II3Altira Technology Fund III1.0American Securities Partners III1.0American Securities Partners IV3.7BioPharma Sec. Debt3.5Brightwood Capital4.5Capital Dynamics Champion Ventures IV1.6Cross Creek Capital3.4Crystal Ridge Partners2.8CSL Energy2.9Easterly Prt US Govt Inc & Growth I3.8North Atlantic Venture6Paul Capital Royalty Fund7Royalty Pharma13.1	013,911 17,013,9 1455,933 49,455,1 307,254 12,807,1 341,294 5,841,1 548,548 18,648,3 110,055 144,110,0 361,706 291,604 323,136 388,133	911 - 933 - 254 - 294 - 548 - 055 - - 21,861,706 - - - 19,323,136 - 8,388,133 - 6,700,295	
Subtotal Global49,4EMERGING MARKETSDimensional Fund Advisors12,8TVC Conduit5,8Subtotal Emerging Markets18,6Subtotal Long Equity144,1HEDGEDNew Generation Turnaround FundNew Mountain Vantage15,2Steelhead Partners19,3Blenheim Commodities Fund8,3High Vista II6,7Subtotal Hedged71,5Total Equity (including limited partnerships)215,6ALTERNATIVE INVESTMENTS1,0Attira Technology Fund II1,0American Securities Partners IV1,9American Securities Partners IV1,9American Securities Partners IV3,7BioPharma Sec. Debt3,5Brightwood Capital4,5Crystal Ridge Partners2,8CSL Energy2,9Easterly Prt US Govt Inc & Growth I3,4Crystal Ridge Partners2,8CSL Energy2,9Easterly Prt US Govt Inc & Growth I6,4Easterly Prt US Govt Inc & Growth I3,1North Atlantic Venture6Paul Capital Royalty Fund7Royalty Pharma13,1	49,455,933 49,455,933 307,254 12,807,133 341,294 5,841,133 548,548 18,648,93 110,055 144,110,93 361,706 291,604 323,136 388,133	933 - 254 - 294 - 548 - 055 - - 21,861,706 - - - 19,323,136 - 8,388,133 - 6,700,295	- - - - - - - - - - - - - - - - - - -
Dimensional Fund Advisors12.8TVC Conduit5.8Subtotal Emerging Markets18.6Subtotal Long Equity144.1HEDGED144.1New Generation Turnaround Fund21.8New Mountain Vantage15.2Steelhead Partners19.3Blenheim Commodities Fund8.3High Vista II6.7Subtotal Hedged71.5Total Equity (including limited partnerships)215.6ALTERNATIVE INVESTMENTS1Altira Technology Fund II3Altira Technology Fund II1,0American Securities Partners III1,0American Securities Partners IV1,9American Securities Partners IV3,5Biopharma Sec. Debt3,5Srightwood Capital4,5Capital Dynamics Champion Ventures IV1,6Cross Creek Capital3,4Crystal Ridge Partners2,8CSL Energy2,9Easterly Prt US Govt Inc & Growth I3,8North Atlantic Venture6Paul Capital Royalty Fund7Royalty Pharma13,1	341,294 5,841,2 348,548 18,648,2 110,055 144,110,0 361,706 291,604 323,136 388,133	294 - 548 - 055 - - 21,861,706 - 19,323,136 - 8,388,133 - 6,700,295	- - - - - - 15,291,604 - -
Dimensional Fund Advisors12.8TVC Conduit5.8Subtotal Emerging Markets18.6Subtotal Long Equity144.1HEDGED144.1New Generation Turnaround Fund21.8New Mountain Vantage15.2Steelhead Partners19.3Blenheim Commodities Fund8.3High Vista II6.7Subtotal Hedged71.5Total Equity (including limited partnerships)215.6ALTERNATIVE INVESTMENTS1Altira Technology Fund II3Altira Technology Fund II1,0American Securities Partners III1,0American Securities Partners IV1,9American Securities Partners IV3,5Biopharma Sec. Debt3,5Srightwood Capital4,5Capital Dynamics Champion Ventures IV1,6Cross Creek Capital3,4Crystal Ridge Partners2,8CSL Energy2,9Easterly Prt US Govt Inc & Growth I3,8North Atlantic Venture6Paul Capital Royalty Fund7Royalty Pharma13,1	341,294 5,841,2 348,548 18,648,2 110,055 144,110,0 361,706 144,110,0 291,604 323,136 388,133 388,133	294 - 548 - 055 - - 21,861,706 - 19,323,136 - 8,388,133 - 6,700,295	-
TVC Conduit5.8Subtotal Emerging Markets18.6Subtotal Long Equity144.1HEDGED144.1New Generation Turnaround Fund21.8New Mountain Vantage15.2Steelhead Partners19.3Blenheim Commodities Fund8,3High Vista II6,7Subtotal Hedged71.5Total Equity (including limited partnerships)215.6ALTERNATIVE INVESTMENTSAltira Technology Fund II3Altira Technology Fund II1,0American Securities Partners IV1,9American Securities Partners IV3,7BioPharma Sec. Debt3,5Capital Dynamics Champion Ventures IV1,6Cross Creek Capital3,4Crystal Ridge Partners2,8CSL Energy2,9Easterly Prt US Govt Inc & Growth I3,8North Atlantic Venture6Paul Capital Royalty Fund7Royalty Pharma13,1	341,294 5,841,2 348,548 18,648,2 110,055 144,110,0 361,706 144,110,0 291,604 323,136 388,133 388,133	294 - 548 - 055 - - 21,861,706 - 19,323,136 - 8,388,133 - 6,700,295	- - - - 15,291,604 - -
Subtotal Emerging Markets18,6Subtotal Long Equity144,1HEDGED21,8New Generation Turnaround Fund21,8New Mountain Vantage15,2Steelhead Partners19,3Blenheim Commodities Fund8,3High Vista II6,7Subtotal Hedged71,5Total Equity (including limited partnerships)215,6ALTERNATIVE INVESTMENTS1,0Altira Technology Fund II3Altira Technology Fund II1,0American Securities Partners III1,0American Securities Partners IV3,7BioPharma Sec. Debt3,5Brightwood Capital4,5Capital Dynamics Champion Ventures IV1,6Cross Creek Capital3,4Crystal Ridge Partners2,8CSL Energy2,9Easterly Prt US Govt Inc & Growth I3,8North Atlantic Venture6Paul Capital Royalty Fund7Royalty Pharma13,1	348,548 18,648,3 110,055 144,110,0 361,706 144,110,0 291,604 323,136 388,133 388,133	548 - 055 - - 21,861,706 - 19,323,136 - 8,388,133 - 6,700,295	
Subtotal Long Equity144,1HEDGED21,8New Generation Turnaround Fund21,8New Mountain Vantage15,2Steelhead Partners19,3Blenheim Commodities Fund8,3High Vista II6,7Subtotal Hedged71,5Total Equity (including limited partnerships)215,6ALTERNATIVE INVESTMENTS3Altira Technology Fund II3Altira Technology Fund II1,0American Securities Partners III1,0American Securities Partners IV3,7BioPharma Sec. Debt3,5Brightwood Capital4,5Capital Dynamics Champion Ventures IV1,6Cross Creek Capital3,4Crystal Ridge Partners2,8CSL Energy2,9Easterly Prt US Govt Inc & Growth II3,8North Atlantic Venture6Paul Capital Royalty Fund7Royalty Pharma13,1	110,055 144,110,0 361,706 291,604 323,136 388,133	055 - 21,861,706 - 19,323,136 - 8,388,133 - 6,700,295	
HEDGEDNew Generation Turnaround Fund21,8New Mountain Vantage15,2Steelhead Partners19,3Blenheim Commodities Fund8,3High Vista II6,7Subtotal Hedged71,5Total Equity (including limited partnerships)215,6ALTERNATIVE INVESTMENTS1Altira Technology Fund II3Altira Technology Fund IV1American Securities Partners III1,0American Securities Partners V3,7BioPharma Sec. Debt3,5Brightwood Capital4,5Cross Creek Capital3,4Cross Creek Capital3,4Crystal Ridge Partners2,8CSL Energy2,9Easterly Prt US Govt Inc & Growth I6,4Easterly Prt US Govt Inc & Growth II3,8North Atlantic Venture6Paul Capital Royalty Fund7Royalty Pharma13,1	361,706 291,604 323,136 388,133	- 21,861,706 19,323,136 - 8,388,133 - 6,700,295	 15,291,604
New Generation Turnaround Fund21,8New Mountain Vantage15,2Steelhead Partners19,3Blenheim Commodities Fund8,3High Vista II6,7Subtotal Hedged71,5Total Equity (including limited partnerships)215,6ALTERNATIVE INVESTMENTS3Altira Technology Fund II3Altira Technology Fund IV1American Securities Partners III1,0American Securities Partners IV1,9American Securities Partners IV3,5Brightwood Capital4,5Capital Dynamics Champion Ventures IV1,6Cross Creek Capital3,4Crystal Ridge Partners2,8CSL Energy2,9Easterly Prt US Govt Inc & Growth I6,4Easterly Prt US Govt Inc & Growth II3,8North Atlantic Venture6Paul Capital Royalty Fund7Royalty Pharma13,1	291,604 323,136 388,133	- 19,323,136 - 8,388,133 - 6,700,295	- 15,291,604 - -
New Mountain Vantage15.2Steelhead Partners19,3Blenheim Commodities Fund8,3High Vista II6,7Subtotal Hedged71,5Total Equity (including limited partnerships)215,6ALTERNATIVE INVESTMENTSAltira Technology Fund II3Altira Technology Fund II3Altira Technology Fund IV1American Securities Partners III1,0American Securities Partners IV3,5Brightwood Capital4,5Capital Dynamics Champion Ventures IV1,6Cross Creek Capital3,4Crystal Ridge Partners2,8CSL Energy2,9Easterly Prt US Govt Inc & Growth I6,4Easterly Prt US Govt Inc & Growth II3,8North Atlantic Venture6Paul Capital Royalty Fund7Royalty Pharma13,1	291,604 323,136 388,133	- 19,323,136 - 8,388,133 - 6,700,295	- 15,291,604 - -
Steelhead Partners19,3Blenheim Commodities Fund8,3High Vista II6,7Subtotal Hedged71,5Total Equity (including limited partnerships)215,6ALTERNATIVE INVESTMENTSAltira Technology Fund II3Altira Technology Fund IV1American Securities Partners III1,0American Securities Partners IV1,9American Securities Partners V3,7BioPharma Sec. Debt3,5Brightwood Capital4,5Capital Dynamics Champion Ventures IV1,6Cross Creek Capital3,4Crystal Ridge Partners2,8CSL Energy2,9Easterly Prt US Govt Inc & Growth I6,4Easterly Prt US Govt Inc & Growth II3,8North Atlantic Venture6Paul Capital Royalty Fund7Royalty Pharma13,1	323,136 388,133	- 8,388,133 - 6,700,295	15,291,604 - -
Blenheim Commodities Fund8,3High Vista II6,7Subtotal Hedged71,5Total Equity (including limited partnerships)215,6ALTERNATIVE INVESTMENTSAltira Technology Fund IIAltira Technology Fund IIIAnerican Securities Partners IIIAmerican Securities Partners IVAmerican Securities Partners VSightwood CapitalCapital Dynamics Champion Ventures IVCross Creek CapitalCrystal Ridge PartnersCSL EnergyEasterly Prt US Govt Inc & Growth IEasterly Prt US Govt Inc & Growth IIAnorh Atlantic VenturePaul Capital Royalty FundTotal Royalty PharmaTaylorTaylorTaylorSolatial Royalty FundTaylorTaylorTaylorSubtotal PharmaTaylorTay	388,133	- 8,388,133 - 6,700,295	-
High Vista II6,7Subtotal Hedged71,5Total Equity (including limited partnerships)215,6ALTERNATIVE INVESTMENTS215,6Altira Technology Fund II3Altira Technology Fund III3Altira Technology Fund IV1American Securities Partners III1,0American Securities Partners IV1,9American Securities Partners V3,7BioPharma Sec. Debt3,5Brightwood Capital4,5Capital Dynamics Champion Ventures IV1,6Cross Creek Capital3,4Crystal Ridge Partners2,8CSL Energy2,9Easterly Prt US Govt Inc & Growth I6,4Easterly Prt US Govt Inc & Growth II3,8North Atlantic Venture6Paul Capital Royalty Fund7Royalty Pharma13,1		- 6,700,295	-
Subtotal Hedged71,5Total Equity (including limited partnerships)215,6ALTERNATIVE INVESTMENTSAltira Technology Fund II3Altira Technology Fund IV1American Securities Partners III1,0American Securities Partners IV1,9American Securities Partners V3,7BioPharma Sec. Debt3,5Brightwood Capital4,5Capital Dynamics Champion Ventures IV1,6Cross Creek Capital3,4Crystal Ridge Partners2,8CSL Energy2,9Easterly Prt US Govt Inc & Growth I6,4Easterly Prt US Govt Inc & Growth II3,8North Atlantic Venture6Paul Capital Royalty Fund7Royalty Pharma13,1	/00,295		
Total Equity (including limited partnerships)215,6ALTERNATIVE INVESTMENTSAltira Technology Fund IIAltira Technology Fund IVAmerican Securities Partners IIIAmerican Securities Partners IVAmerican Securities Partners VBioPharma Sec. DebtBrightwood CapitalCapital Dynamics Champion Ventures IVCross Creek CapitalCSL EnergyEasterly Prt US Govt Inc & Growth IEasterly Prt US Govt Inc & Growth IINorth Atlantic VenturePaul Capital Royalty FundTotal Right Pharma13,1		56 272 270	-
ALTERNATIVE INVESTMENTS Altira Technology Fund II Altira Technology Fund III Altira Technology Fund IV American Securities Partners III American Securities Partners IV American Securities Partners V BioPharma Sec. Debt Brightwood Capital Capital Dynamics Champion Ventures IV Cross Creek Capital CSL Energy Easterly Prt US Govt Inc & Growth I Easterly Prt US Govt Inc & Growth II North Atlantic Venture Paul Capital Royalty Fund Topolatial Royalty Fund Topolatial Royalty Pharma	564,874	- 56,273,270	15,291,604
Altira Technology Fund II3Altira Technology Fund III3Altira Technology Fund IV1American Securities Partners III1,0American Securities Partners IV1,9American Securities Partners V3,7BioPharma Sec. Debt3,5Brightwood Capital4,5Capital Dynamics Champion Ventures IV1,6Cross Creek Capital3,4Crystal Ridge Partners2,8CSL Energy2,9Easterly Prt US Govt Inc & Growth I6,4Easterly Prt US Govt Inc & Growth II3,8North Atlantic Venture6Paul Capital Royalty Fund7Royalty Pharma13,1	674,929 144,110,	055 56,273,270	15,291,604
Altira Technology Fund II3Altira Technology Fund III3Altira Technology Fund IV1American Securities Partners III1,0American Securities Partners IV1,9American Securities Partners V3,7BioPharma Sec. Debt3,5Brightwood Capital4,5Capital Dynamics Champion Ventures IV1,6Cross Creek Capital3,4Crystal Ridge Partners2,8CSL Energy2,9Easterly Prt US Govt Inc & Growth I6,4Easterly Prt US Govt Inc & Growth II3,8North Atlantic Venture6Paul Capital Royalty Fund7Royalty Pharma13,1			
Altira Technology Fund III3Altira Technology Fund IV1American Securities Partners III1,0American Securities Partners IV1,9American Securities Partners V3,7BioPharma Sec. Debt3,5Brightwood Capital4,5Capital Dynamics Champion Ventures IV1,6Cross Creek Capital3,4Crystal Ridge Partners2,8CSL Energy2,9Easterly Prt US Govt Inc & Growth I6,4Easterly Prt US Govt Inc & Growth II3,8North Atlantic Venture6Paul Capital Royalty Fund7Royalty Pharma13,1	71,556		71,556
Altira Technology Fund IV1American Securities Partners III1,0American Securities Partners IV1,9American Securities Partners V3,7BioPharma Sec. Debt3,5Brightwood Capital4,5Capital Dynamics Champion Ventures IV1,6Cross Creek Capital3,4Crystal Ridge Partners2,8CSL Energy2,9Easterly Prt US Govt Inc & Growth I6,4Easterly Prt US Govt Inc & Growth II3,8North Atlantic Venture6Paul Capital Royalty Fund7Royalty Pharma13,1	310,573		310,573
American Securities Partners III1,0American Securities Partners IV1,9American Securities Partners V3,7BioPharma Sec. Debt3,5Brightwood Capital4,5Capital Dynamics Champion Ventures IV1,6Cross Creek Capital3,4Crystal Ridge Partners2,8CSL Energy2,9Easterly Prt US Govt Inc & Growth I6,4Easterly Prt US Govt Inc & Growth II3,8North Atlantic Venture6Paul Capital Royalty Fund7Royalty Pharma13,1	18,600		118,600
American Securities Partners IV1,9American Securities Partners V3,7BioPharma Sec. Debt3,5Brightwood Capital4,5Capital Dynamics Champion Ventures IV1,6Cross Creek Capital3,4Crystal Ridge Partners2,8CSL Energy2,9Easterly Prt US Govt Inc & Growth I6,4Easterly Prt US Govt Inc & Growth II3,8North Atlantic Venture6Paul Capital Royalty Fund7Royalty Pharma13,1	053,008		1,053,008
BioPharma Sec. Debt3,5Brightwood Capital4,5Capital Dynamics Champion Ventures IV1,6Cross Creek Capital3,4Crystal Ridge Partners2,8CSL Energy2,9Easterly Prt US Govt Inc & Growth I6,4Easterly Prt US Govt Inc & Growth II3,8North Atlantic Venture6Paul Capital Royalty Fund7Royalty Pharma13,1	931,089		1,931,089
Brightwood Capital4,5Capital Dynamics Champion Ventures IV1,6Cross Creek Capital3,4Crystal Ridge Partners2,8CSL Energy2,9Easterly Prt US Govt Inc & Growth I6,4Easterly Prt US Govt Inc & Growth II3,8North Atlantic Venture6Paul Capital Royalty Fund7Royalty Pharma13,1	767,694		3,767,694
Capital Dynamics Champion Ventures IV1,6Cross Creek Capital3,4Crystal Ridge Partners2,8CSL Energy2,9Easterly Prt US Govt Inc & Growth I6,4Easterly Prt US Govt Inc & Growth II3,8North Atlantic Venture6Paul Capital Royalty Fund7Royalty Pharma13,1	532,209		3,532,209
Cross Creek Capital3,4Crystal Ridge Partners2,8CSL Energy2,9Easterly Prt US Govt Inc & Growth I6,4Easterly Prt US Govt Inc & Growth II3,8North Atlantic Venture6Paul Capital Royalty Fund7Royalty Pharma13,1	538,814		4,538,814
Crystal Ridge Partners2,8CSL Energy2,9Easterly Prt US Govt Inc & Growth I6,4Easterly Prt US Govt Inc & Growth II3,8North Atlantic Venture6Paul Capital Royalty Fund7Royalty Pharma13,1	611,710		1,611,710
CSL Energy2,9Easterly Prt US Govt Inc & Growth I6,4Easterly Prt US Govt Inc & Growth II3,8North Atlantic Venture6Paul Capital Royalty Fund7Royalty Pharma13,1	133,586		3,433,586
Easterly Prt US Govt Inc & Growth I6,4Easterly Prt US Govt Inc & Growth II3,8North Atlantic Venture6Paul Capital Royalty Fund7Royalty Pharma13,1	347,609		2,847,609
Easterly Prt US Govt Inc & Growth II3,8North Atlantic Venture6Paul Capital Royalty Fund7Royalty Pharma13,1	986,119		2,986,119
North Atlantic Venture6Paul Capital Royalty Fund7Royalty Pharma13,1	120,440		6,420,440
Paul Capital Royalty Fund7Royalty Pharma13,1	332,209 600,000		3,832,209 600,000
Royalty Pharma 13,1	78,305		778,305
	165,459		13,165,459
TIFF Partners II	96,708		96,708
	228,163		2,228,163
	727,216		1,727,216
	302,871		2,302,871
	346,816		7,346,816
TIFF Private Equity Partners 2008 11,4	175,889		11,475,889
TIFF Secondary Partners II 3,1	10,642		3,110,642
TIFF Special Opportunities 2,0	062,890		2,062,890
Venture Investment 2,7		<u> </u>	2,768,944
Total Alternatives Investments84,1	768,944	<u> </u>	84,119,119
FIXED INCOME	768,944 19,119		
		- 16,561,564	-
·	19,119		-
	561,564		-
-	19,119		
	561,564 004,110 2,004,		
Total Portfolio <u>\$ 328,3</u> See independent auditors' report	119,119 561,564 004,110 2,004, 015,830 10,015, 581,504 12,019,	940 16,561,564	\$ 99,410,723

Schedule of Functional Expenses Year Ended December 31

		2014				2013			
	Program Services	Operations and Governance	Investment	Total	Program Services	Operations and Governance	Investment	Total	
				Total					
Grants authorized, net	<u>\$ 10,963,903</u>	<u>\$ -</u>	<u>\$</u> -	\$ 10,963,903	<u>\$ 10,680,794</u>	<u>\$ -</u>	<u>\$ -</u>	\$ 10,680,794	
ALLOCATED EXPENSES									
Salaries and wages	1,486,289	538,511	129,242	2,154,042	1,457,709	528,156	126,757	2,112,622	
Payroll taxes and employee benefits	710,631	257,475	61,794	1,029,900	669,793	242,679	58,243	970,715	
Occupancy	744,217	269,644	64,715	1,078,576	746,748	270,561	64,935	1,082,244	
Furniture and maintenance	36,805	13,336	3,201	53,342	23,077	8,362	2,007	33,446	
Office expenses	37,611	13,627	3,271	54,509	36,500	13,225	3,174	52,899	
General expenses	83,309	30,185	7,244	120,738	158,429	57,402	13,776	229,607	
Staff travel and expense	78,090	28,294	6,790	113,174	72,326	26,205	6,289	104,820	
Telecommunications	25,925	9,393	2,254	37,572	29,572	10,715	2,571	42,858	
Computer purchases and maintenance	47,185	17,096	4,103	68,384	50,093	18,150	4,356	72,599	
Professional fees	48,152	17,447	4,187	69,786	62,674	22,708	5,450	90,832	
Insurance	35,068	12,706	3,049	50,823	33,500	12,138	2,913	48,551	
Trustee and committee expenses	81,572	29,555	7,093	118,220	91,317	33,086	7,941	132,344	
Total Allocated Expenses	3,414,854	1,237,269	296,943	4,949,066	3,431,738	1,243,387	298,412	4,973,537	
DIRECT PROGRAM EXPENSES									
Publications	27,079	-	-	27,079	19,250	-	-	19,250	
Advisory expenses	551,932			551,932	497,462			497,462	
Total Direct Program Expenses	579,011			579,011	516,712			516,712	
DIRECT INVESTMENT EXPENSE									
Manager fees	-	-	667,407	667,407	-	-	605,106	605,106	
Custody fees	-	-	121,152	121,152	-	-	112,249	112,249	
Consulting expenses			603	603			2,678	2,678	
Total Direct Investment Expenses			789,162	789,162			720,033	720,033	
Total	<u>\$ 14,957,768</u>	<u>\$ 1,237,269</u>	<u>\$ 1,086,105</u>	<u>\$ 17,281,142</u>	<u>\$ 14,629,244</u>	<u>\$ 1,243,387</u>	<u>\$ 1,018,445</u>	<u>\$ 16,891,076</u>	